Pantocalcin, pills 500mg, 50pcs

Composition

1 tablet contains: Active ingredient: hopantenic acid-250.00 mg or 500.00 mg; excipients: magnesium hydroxycarbonate, calcium stearate, talc, potato starch.

Pharmacological action

Pharmacodynamics

The spectrum of action is associated with the presence of gamma-aminobutyric acid in the structure. The mechanism of action is due to the direct effect of pantocalcin on the GABAB-receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties. Increases the brain’s resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons. It has an anticonvulsant effect, reduces motor excitability with simultaneous ordering of behavior. Increases mental and physical performance.

Promotes normalization of the content of gamma-aminobutyric acid in chronic alcohol intoxication and subsequent withdrawal of ethanol. It has an analgesic effect. It is able to inhibit acetylation reactions involved in the mechanisms of inactivation of novocaine and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of pathologically elevated cystic reflex and detrusor tone.

Pharmacokinetics

It is rapidly absorbed in the gastrointestinal tract. The time to reach the maximum concentration in blood plasma is 1 h. The highest concentrations are created in the liver, kidneys, stomach wall, and skin. Penetrates the blood-brain barrier. It is not metabolized. It is excreted unchanged for 48 hours(67.5% of the dose taken – in the urine,28.5% – in the feces).

Indications

• Cognitive disorders in organic brain lesions and inflammatory conditions;
• in the complex therapy of cerebrovascular insufficiency caused by atherosclerotic changes in vessels of the brain; senile dementia (primary form), residual organic brain lesions in people of Mature age and older;
• cerebral organic insufficiency in patients with schizophrenia (in combination with neuroleptics, antidepressants);
• extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (including Huntington’s chorea, hepatolenticular degeneration, Parkinson’s disease);
• the consequences of neuroinfections and traumatic brain injury (in the complex therapy);
• correction and prevention (therapy cover while the appointment) side effects of antipsychotics; extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic);
• epilepsy with slowing of mental processes (in combination with anticonvulsants);
• psycho-emotional overload, reduced mental and physical performance; to improve concentration and memory;
• urinary disorders: enuresis, daytime urinary incontinence, pollakiuria, imperative urges;

Children:

• mental retardation (delayed mental, speech, motor development or a combination of these);
• cerebral palsy;
• stuttering (mainly clonic form);
• epilepsy (in combination therapy with anticonvulsants, especially in polymorphic seizures and minor epileptic seizures).

Use during pregnancy and lactation

Contraindicated in the first trimester of pregnancy.

Contraindications

• Hypersensitivity;
• acute renal failure;
• pregnancy (1 trimester).

Side effects

Possible allergic reactions (rhinitis, conjunctivitis, skin rashes).

Interaction

The effect of hopantenic acid is enhanced in combination with glycine, xidiphone. Prolongs the action of barbiturates; enhances the effects of drugs that stimulate the central nervous system, anticonvulsants, and local anesthetics (procaine). Prevents the side effects of the following drugs: phenobarbital, carbamazepine, antipsychotics (neuroleptics).

How to take, course of use and dosage

Inside.

Take 15-30 minutes after meals.

A single dose for adults is 0.5-1 g, for children — 0.25-0.5 g, daily-1.5-3 g (for adults),0.75-3 g (for children). The duration of the course of treatment is from 1 to 4 months, in some cases-up to 6 months. After 3-6 months, it is possible to conduct a second course of treatment.

Children. Mental disability-0.5 g 4-6 times a day, daily for 3 months. Delayed speech development — 0.5 g 3-4 times a day for 2-3 months.

Neuroleptic syndrome (as a corrector of the side effect of neuroleptics). Adults-0.5-1 g 3 times a day; children-0.25-0.5 g 3-4 times a day. The duration of treatment is 1-3 months.

Epilepsy. Children-0.25-0.5 g 3-4 times a day; adults-0.5-1 g 3-4 times a day daily for a long time (up to 6 months).

Hyperkinesis (tics). Children-0.25-0.5 g 3-6 times a day daily for 1-4 months; adults-1.5-3 g a day daily for 1-5 months.

Disorders of urination. Adults-0.5-1 g 2-3 times a day (daily dose-2-3 g); children-0.25-0.5 g (daily dose-25-50 mg / kg). The duration of the course of treatment is from 2 weeks to 3 months (depending on the severity of the disorders and the therapeutic effect).

Consequences of neuroinfections and traumatic brain injuries. 0,25 g 3-4 times a day.

To restore working capacity under increased loads and asthenic conditions. 0.25 g 3 times a day.

This dosage form is not recommended for children under 3 years of age.

Overdose

Symptoms: characterized by increased severity of side effects. Treatment: gastric lavage, use of activated charcoal, symptomatic therapy.

Description

Round flat-cylindrical tablets of white color with a chamfer and a risk for a dosage of 500 mg, with a chamfer and a cross-shaped risk for a dosage of 250 mg.

Form of production

Tablets of 250 mg or 500 mg. 10 tablets in a contour cell package or in a contour cell package with perforation made of polyvinyl chloride film and aluminum foil printed varnished. 50 tablets are placed in polymer cans complete with lids. Each jar,5 contour packages together with the instructions for use are placed in a pack of cardboard.

Storage conditions

In a dark place at a temperature not exceeding 25°C. Keep out of reach of children.

Shelf

life is 4 years. Do not use after the expiration date.

Active ingredient

Hopanthenic acid

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as prescribed by a doctor, for children as prescribed by a doctor

Indications

Acquired Dementia, Neurosis, Cerebrovascular accident, Concussion and other traumatic brain injuries, Epilepsy